About Bacterial Conjunctivitis Drugs
Bacterial conjunctivitis, which affects either one or both the eyes, is an extremely contagious eye condition wherein the conjunctiva is infected. Staphylococci, streptococci, gonococci, and Chlamydia are some of the causative agents of bacterial conjunctivitis. Extremely pathogenic bacteria such as Chlamydia trachomatis and Neisseria gonorrhea cause severe bacterial conjunctivitis. Antibiotics help in eradicating the microbes, resulting in faster clearance of the symptoms. Broad-spectrum antibiotics such as Besivance, Zymaxid, Maxitrol, and AzaSite, in the form of antibiotic pills, ointment, or eye drops help treat the infection. Fluoroquinolones, macrolides, aminoglycosides, and phenicols are among the different classes of antibiotics that are commonly prescribed to treat the condition.
Technavio’s analysts forecast the global bacterial conjunctivitis drugs market to grow at a CAGR of 2.77% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global bacterial conjunctivitis drugs market for 2015-2020. To calculate the market size, it considers revenue generated from the sales of branded and generic drugs along with over-the-counter (OTC) drugs used to treat bacterial conjunctivitis.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Bacterial Conjunctivitis Drugs Market 2016-2020
Technavio recognizes the following companies as the key players in the Global Bacterial Conjunctivitis Drugs Market: Akorn, Alcon, Allergan and Bausch & Lomb.
Other Prominent Vendors in the market are: Bayer, Daiichi Sankyo, F. Hoffmann-La Roche, InSite Vision, Merck, Nicox, Novartis, Perrigo, Pfizer, Santen Pharmaceutical, Shire and Valeant Pharmaceuticals.
Commenting on the report, an analyst from Technavio’s team said: “The patient assistance programs for conjunctivitis are expected to boost the growth of the market during the forecast period. Vendors are providing co-pay assistance to patients who purchase medications for conjunctivitis. For instance, Bausch & Lomb provides patient assistance programs for patients who are not covered by any private or government insurances. It provides assistance programs for drugs such as Besivance, Alrex, and Zylet, which are used to treat ophthalmic indications. Since the drug suppliers provide the assistance programs, patients are inclined toward buying branded therapies.”
According to the report, the rising awareness about conjunctivitis has resulted in an understanding about how to prevent and control the infection. This has been possible because of numerous awareness programs.
Further, the report states that Patent expiries result in the entry of generics, leading to a decline in the sales of branded drugs. The generics are usually just as effective and safe as the original drugs and come with the added advantage of lower costs. This will result in a major decline in the overall revenue of the market.
Akorn, Alcon, Allergan and Bausch & Lomb, Bayer, Daiichi Sankyo, F. Hoffmann-La Roche, InSite Vision, Merck, Nicox, Novartis, Perrigo, Pfizer, Santen Pharmaceutical, Shire, Valeant Pharmaceuticals.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook